Work

Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.2602

Authors: Amita Patnaik, Patricia LoRusso, Howard A. Ball, Erkut Bahceci, Geoffrey Yuen, Kyriakos P. Papadopoulos, Muaiad Kittaneh, Anthony W. Tolcher

Institutions: South Texas Accelerated Research Therapeutics, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Astellas Pharma (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2595746152

Cites:

Cited by: 19

Related to: 10